Abstract
Several observations in mice and in humans have collectively laid the foundation for examining the potential of γ δ T cells to exert tumor immunotherapy. Human γ δ T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of γ δ T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.
Keywords: Human γ δ T cells, tumors, phosphoantigens, bisphosphonates, immunotherapy
Current Medicinal Chemistry
Title: Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer
Volume: 15 Issue: 12
Author(s): Nadia Caccamo, Serena Meraviglia, Giuseppe Cicero, Gaspare Gulotta, Francesco Moschella, Adriana Cordova, Eliana Gulotta, Alfredo Salerno and Francesco Dieli
Affiliation:
Keywords: Human γ δ T cells, tumors, phosphoantigens, bisphosphonates, immunotherapy
Abstract: Several observations in mice and in humans have collectively laid the foundation for examining the potential of γ δ T cells to exert tumor immunotherapy. Human γ δ T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of γ δ T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.
Export Options
About this article
Cite this article as:
Caccamo Nadia, Meraviglia Serena, Cicero Giuseppe, Gulotta Gaspare, Moschella Francesco, Cordova Adriana, Gulotta Eliana, Salerno Alfredo and Dieli Francesco, Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer, Current Medicinal Chemistry 2008; 15 (12) . https://dx.doi.org/10.2174/092986708784310468
DOI https://dx.doi.org/10.2174/092986708784310468 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Treating Age-Related Macular Degeneration – Interaction of VEGF-Antagonists with their Target
Mini-Reviews in Medicinal Chemistry A Review on the Neuroprotective Effect of Berberine against Chemotherapy- induced Cognitive Impairment
Current Drug Targets VEGF/VEGFR2 Autocrine Signaling Stimulates Metastasis in Prostate Cancer Cells
Current Angiogenesis (Discontinued) Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Anti-Cancer Agents in Medicinal Chemistry Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Role of Preoperative Diagnostic Imaging Procedures in Secondary Hyperparathyroidism
Current Medical Imaging Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry The Hormetic Role of Dietary Antioxidants in Free Radical-Related Diseases
Current Pharmaceutical Design Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Finding Relevant Genes Involved in the Cytotoxicity Mechanisms of Anticancer Biophores
Current Computer-Aided Drug Design Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design Therapeutic Proteins: A to Z
Protein & Peptide Letters Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology